February 26, 2021
Business News

Indee Labs Awarded Contract from the National Cancer Institute


BERKELEY, Calif.–()–Indee Labs is a biotechnology company developing the µVS Delivery SystemTM for non-viral intracellular or gene delivery. The team at Indee Labs was recently awarded a contract from the National Cancer Institute to develop the µVS Delivery SystemTM for T cell immunotherapy discovery, development and manufacturing.

“T cell immunotherapies have revolutionized how we treat disease; however, the processes to discovery, develop and manufacture these interventions are fraught with issues. We’re excited to be supported by the NCI to develop our novel, non-viral gene delivery system called the µVS Delivery SystemTM to insert transgenes for CAR-T and TCR-T cell products at clinical scale at a…



Click here to view the original article.

Related Posts

You might also like ...

Insight School of Oklahoma Now Accepting Enrollments for 2021-2022 School Year
Set Your Children Up For Success: iQ Academy Minnesota Now Accepting Enrollments for 2021-2022 School Year
Moldy Vortex: ServiceMaster Restore Warns Winter Storm ’21 May Have Lingering, Unhealthy Effects